Milo Taylor, a postbaccalaureate fellow at the NIH, is studying how immune cells recognize and fight infections. Her research ...

A saliva test may ultimately serve as a potential marker of therapeutic response to IFN beta-1a in multiple sclerosis patients.

Immunologists at UNIGE have revealed a previously unknown anti-tumor role of CD4 T lymphocytes, marking a breakthrough that ...

Cite this: Saliva Soluble HLA as a Potential Marker of Response to Interferon-β1a in Multiple Sclerosis: A Preliminary Study - Medscape - Jul 01, 2007.

A new study shows that patients achieve good outcomes with a partial match drawn from the national public registry of donors when they are treated with the immune-suppressing drug cyclophosphamide.

Whether antiretroviral therapy (ART) is always completely suppressive, or HIV might continue to replicate at low levels despite ART in some people with HIV (PWH), is still debated. Here, we ...

In the fight against cancer, immunotherapy—which aims to boost the body's natural defenses against cancer—is experiencing ...

This is because HLA markers used in matching are inherited. Some ethnic groups have more complex tissue types than others.

Partial matches, favorable outcomes A matched donor has a fully compatible set of immune system proteins on their cells, called HLA markers.

Partial Matches, Favorable Outcomes A matched donor has a fully compatible set of immune system proteins on their cells, called HLA markers.